P279. Safety and Tolerability Profile of Zuranolone From the LANDSCAPE (Major Depressive Disorder) and NEST (Postpartum Depression) Clinical Development Programs
Biological Psychiatry(2022)
摘要
Zuranolone is an investigational, rapidly acting, oral neuroactive steroid and GABA type A receptor positive allosteric modulator in clinical development for once-daily, 2-week treatment of major depressive disorder (MDD) and postpartum depression (PPD). Here, we summarize safety data from 4 completed placebo-controlled trials in the zuranolone clinical development program.
更多查看译文
关键词
Major Depressive Disorder (MDD), Postpartum Depression, Safety
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要